Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28931267 | 0.96 | KMT2A (0.50) | KMT2AMEN1ALDH1A1HPGDHDAC8 | |
| SCHEMBL28931266 | 0.96 | KMT2A (0.50) | KMT2AMEN1ALDH1A1HPGDHDAC8 | |
| SCHEMBL557437 | 0.94 | KMT2A (0.48) | KMT2AMEN1ALDH1A1HPGDACE | |
| SCHEMBL15387284 | 0.93 | KMT2A (0.58) | KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL15387285 | 0.93 | KMT2A (0.58) | KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL15387350 | 0.93 | KMT2A (0.58) | KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL30776077 | 0.93 | POLB (0.49) | KMT2AMEN1ALDH1A1HPGDACE | |
| SCHEMBL4396674 | 0.92 | KMT2A (0.45) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL17746944 | 0.89 | KMT2A (0.44) | KMT2AHDAC8ACE | |
| SCHEMBL17747009 | 0.89 | KMT2A (0.44) | KMT2AHDAC8ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | KMT2A 616/4885MEN1 4217/4885ALDH1A1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.